Law Offices of Thomas J. Lamb

  • About Our Firm
  • Drug Injury
  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Breast Implants
  • Free Case Evaluation
  • FAQs

Immunotherapy Making Headway in SCLC and Mesothelioma

March 21, 2018 By Law Offices of Thomas J. Lamb, P.A.

Immune-based therapies continue to show promising signals for patients with small cell lung cancer (SCLC) and mesothelioma, but better predictive biomarkers are needed to determine who is most likely to benefit, according to Justin F. Gainor, MD.

The rationale for immunotherapy in SCLC is growing because it is a very molecularly complex disease, Gainor said in a presentation during the 5th Annual Miami Lung Cancer Conference. While PD-L1 expression is infrequent in this space, SCLC tumors can be characterized by relatively high tumor mutation burden (TMB).

“We’ve seen responses with PD-1 monotherapy as well as with dual checkpoint blockade regardless of PD-L1 status,” said Gainor, assistant professor of medicine at Harvard Medical School and an assistant in medicine at Massachusetts General Hospital. “The combination of PD-1/CTLA-4 is associated with a higher response rate compared with nivolumab alone, but this benefit appears to be most pronounced in high TMB patients.”

Signals with checkpoint inhibitors were first reported with pembrolizumab (Keytruda) in the multi-cohort KEYNOTE-028 trial, which showed that the PD-1 inhibitor pembrolizumab was associated with a 33% overall response rate (ORR) in patients with PD-L1-positive SCLC. Of all patients enrolled on the study, 31.7% tested PD-L1 positive, defined as ?1% PD-L1 expression in tumor and inflammatory cells or stroma.

Nivolumab (Opdivo) has also been investigated in several SCLC studies. The open-label, phase I/II CheckMate-032 trial, for example, evaluated 216 patients with progressive SCLC who had received ?1 prior platinum-containing regimen and were not stratified for PD-L1 expression. Patients were randomly assigned to single-agent nivolumab or the combination of nivolumab and ipilimumab (Yervoy) at 1 of 2 doses.

[Article continues at original source]

 Mesothelioma, Asbestos, and Legal Compensation: Basic Facts

Asbestos-Mesothelioma Case Evaluation Form
Free.  Confidential.  No Obligation.

Filed Under: Asbestos, Mesothelioma

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Either way, you will get Mr. Lamb’s impressions about your case — and not that of a junior lawyer, paralegal, or (worse yet) some case-intake person.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • Drug Injury Cases
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • GenX Cancer Cases
  • Breast Implant Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • About Our Firm
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Attorney Tom Lamb

Mr. Lamb is recognized by other lawyers as practicing law at the highest level of professional experience in terms of legal ability and ethical standards — which is indicated by an AV® Preeminent™ 5.0 out of 5 rating (highest classification) rating from the Martindale-Hubbell® Lawyer Directory.

More importantly, he received the Martindale-Hubbell® Client Distinction Award, which recognizes excellence for:

Quality of Service
Overall Value
Responsiveness
Communication Ability

Read More About Tom Lamb

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma
Asbestos HUB

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2019 · Law Offices of Thomas J. Lamb, P.A.